RT Journal Article
SR Electronic
T1 Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.05.02.442326
DO 10.1101/2021.05.02.442326
A1 Elaine C. Chen
A1 Pavlo Gilchuk
A1 Seth J. Zost
A1 Naveenchandra Suryadevara
A1 Emma S. Winkler
A1 Carly R. Cabel
A1 Elad Binshtein
A1 Rachel E. Sutton
A1 Jessica Rodriguez
A1 Samuel Day
A1 Luke Myers
A1 Andrew Trivette
A1 Jazmean K. Williams
A1 Edgar Davidson
A1 Shuaizhi Li
A1 Benjamin J. Doranz
A1 Samuel K. Campos
A1 Robert H. Carnahan
A1 Curtis A. Thorne
A1 Michael S. Diamond
A1 James E. Crowe, Jr
YR 2021
UL http://biorxiv.org/content/early/2021/05/03/2021.05.02.442326.abstract
AB Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes, which have been seen in responses to different infectious diseases as well as healthy individuals. Here we identify 37 public clonotypes in memory B cells from convalescent survivors of SARS-CoV-2 infection or in plasmablasts from an individual after vaccination with mRNA-encoded spike protein. We identified 29 public clonotypes, including clones recognizing the receptor-binding domain (RBD) in the spike protein S1 subunit (including a neutralizing, ACE2-blocking clone that protects in vivo), and others recognizing non-RBD epitopes that bound the heptad repeat 1 region of the S2 domain. Germline-revertant forms of some public clonotypes bound efficiently to spike protein, suggesting these common germline-encoded antibodies are preconfigured for avid recognition. Identification of large numbers of public clonotypes provides insight into the molecular basis of efficacy of SARS-CoV-2 vaccines and sheds light on the immune pressures driving the selection of common viral escape mutants.Competing Interest StatementE.D. and B.J.D. are employees of Integral Molecular, and B.J.D.is a shareholder in that company. M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and Carnival Corporation and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. J.E.C. has served as a consultant for Eli Lilly, GlaxoSmithKline and Luna Biologics, is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines and is Founder of IDBiologics. The Crowe laboratory has received funding support in sponsored research agreements from AstraZeneca, IDBiologics, and Takeda. All other authors declare no competing interests.